论文部分内容阅读
目的:观察司帕沙星治疗细菌性呼吸道感染的疗效及安全性。方法:136例细菌性呼吸道感染患者随机分为2组,治疗组68例给予司帕沙星0.2 g,ivd,qd;对照组68例给予头孢曲松3.0 g,ivd,qd,均以7 d为一疗程。结果:治疗组与对照组在临床疗效、细菌清除率、安全性方面差异均无统计学意义(P>0.05)。结论:司帕沙星治疗临床常见病原菌引起的呼吸道感染疗效确切可靠。
Objective: To observe the efficacy and safety of sparfloxacin in the treatment of bacterial respiratory tract infections. Methods: One hundred and sixty-six patients with bacterial respiratory tract infection were randomly divided into two groups. 68 cases in the treatment group were given sparfloxacin 0.2 g, ivd, qd, and 68 cases in the control group were given ceftriaxone 3.0 g, ivd, qd for 7 days For a course of treatment. Results: There was no significant difference between the treatment group and the control group in clinical efficacy, bacterial clearance and safety (P> 0.05). Conclusion: Sparfloxacin treatment of common clinical pathogens caused by respiratory tract infection effect is reliable.